|Articles|July 1, 1998

New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure
Volume 4
Issue 7 Suppl

Rationale for Angiotensin Receptor Blockers in Congestive Heart Failure

Author(s)Alan H. Gradman, MD

Download PDF: Rationale for Angiotensin Receptor Blockers in Congestive Heart Failure

Articles in this issue

about 28 years ago

Article

Participating Faculty

about 28 years ago

Article

Introduction: Current Concepts in Hypertension Management and A Look Toward the Future

about 28 years ago

Article

The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

about 28 years ago

Article

Gene Polymorphism Influences Response to Angiotensin Blockade

about 28 years ago

Article

New Drug Class Offers Benefits in Heart Failure

about 28 years ago

Article

Comparative Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocking Agents on Left Ventricular Volumes in Elderly Patients with Heart Failure

about 28 years ago

Article

Phase I Results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) Trial

about 28 years ago

Article

European Society of Cardiology: Angiotensin II Antagonists: Why is There So Much Excitement?

about 28 years ago

Article

What are the Pharmacological Differences Between Angiotensin II Antagonists

about 28 years ago

Article

Clinical Implications of Differences Between Angiotensin II Antagonists

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Rationale for Angiotensin Receptor Blockers in Congestive Heart Failure

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care